Insulin Glulisine in Adult Subjects With Type 2 Diabetes Receiving Insulin Glargine as Basal Insulin

Inclusion Criteria: * Diagnosis of type 2 diabetes mellitus for at least six months; 18 to 70 years of age, inclusive. * A1c ≥ 7.0% and ≤ 10% at screening * At least 3 months of continuous insulin and/or insulin analogue therapy (on at least 2 injections) +/- metformin prior to study entry. (Note: Subjects receiving insulin glargine \[Lantus\] twice a day \[split dose\] will be considered as being on one injection only.) * Willingness of subject to discontinue other anti-diabetic drug treatments and to remain off them through the entire study * Negative glutamic acid decarboxylase (GAD) autoantibodies * Ability and willingness to perform self-monitoring of blood glucose (SMBG) at least four times a day, and at least 7 times daily during the 7-point blood glucose (BG) profile measurement days * Ability and willingness to adhere to, and be compliant with, the study protocol * Must be able to read English at the sixth grade level in order to complete the patient-reported outcomes component of the study. * Signed informed consent Exclusion Criteria: * Subjects treated with sulfonylureas, thiazolidinediones (TZDs), or any other oral antidiabetic drugs (within the 3 months before study entry) except for insulin and/or insulin analogues with or without metformin * Planned pregnancy; or pregnant or lactating females. * For subjects treated with metformin: serum creatinine ≥ 1.5 mg/dL (133 µmol/L) for males or ≥ 1.4 mg/dL (124 µmoL) for females * Serum creatinine ≥ 3.0 mg/dL (266 µmol/L) * Any clinically significant renal disease (other than proteinuria) or hepatic disease * Serum ALT or AST levels greater than 2.5 X the upper limit of normal * Any current malignancy or any cancer within the past 5 years (except for adequately treated basal cell skin cancer or cervical carcinoma in situ) * Diagnosis of dementia or mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study * Diagnosis of impaired dexterity or vision rendering the subject unable to administer multiple daily injections (MDIs) * Cardiac status New York Heart Association (NYHA) III-IV * Hypersensitivity to Lantus or insulin glulisine (Apidra) or any of their components * Any disease or condition (including abuse of illicit drugs, prescription medicines or alcohol) that, in the opinion of the investigator or sponsor, may interfere with the completion of the study. * Subject unlikely to comply with protocol, e.g., uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study * Subject is the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol.